A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Deepak L. Bhatt, MD, MPH
Brigham and Women's Hospital, 75 Francis Street, Boston
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
410 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Amarin Investigational Site
Camperdown, New South Wales, Australia
- Amarin Investigational Site
Lismore, New South Wales, Australia
- Amarin Investigational Site
Brisbane, Queensland, Australia
- Amarin Investigational Site
Chermside, Queensland, Australia
- Amarin Investigational Site
Bedford Park, South Australia, Australia
- Amarin Investigational Site
Launceston, Tasmania, Australia
- Amarin Investigational Site
Fitzroy, Victoria, Australia
- Amarin Investigational Site
Geelong, Victoria, Australia
- Amarin Investigational Site
Heidelberg Heights, Victoria, Australia
- Amarin Investigational Site
Melbourne, Victoria, Australia
- Amarin Investigational Site
Fremantle, Western Australia, Australia
- Amarin Investigational Site
Joondalup, Western Australia, Australia
- Amarin Investigational Site
Murdoch, Western Australia, Australia
- Amarin Investigational Site
Nedlands, Western Australia, Australia
- Amarin Investigational Site
Perth, Western Australia, Australia
- Amarin Investigational Site
Edmonton, Alberta, Canada
- Amarin Investigational Site
Coquitlam, British Columbia, Canada
- Amarin Investigational Site
Vancouver, British Columbia, Canada
- Amarin Investigational Site
Vancouver, British Columbia, Canada
- Amarin Investigational Site
Brampton, Ontario, Canada
- Amarin Investigational Site
Collingwood, Ontario, Canada
- Amarin Investigational Site
Corunna, Ontario, Canada
- Amarin Investigational Site
Newmarket, Ontario, Canada
- Amarin Investigational Site
Sarnia, Ontario, Canada
- Amarin Investigational Site
Strathroy, Ontario, Canada
- Amarin Investigational Site
Laval, Quebec, Canada
- Amarin Investigational Site
Montreal, Quebec, Canada
- Amarin Investigational Site
Montreal, Quebec, Canada
- Amarin Investigational Site
Saint-Charles-Borromée, Quebec, Canada
- Amarin Investigational Site
Sherbrooke, Quebec, Canada
- Amarin Investigational Site
Québec, Canada
- Amarin Investigational Site
Québec, Canada
- Amarin Investigational Site
Hyderabad, Andhra Pradesh, India
- Amarin Investigational Site
Hyderabad, Andhra Pradesh, India
- Amarin Investigational Site
Secunderabad, Andhra Pradesh, India
- Amarin Investigational Site
Visakhapatnam, Andhra Pradesh, India
- Amarin Investigational Site
Bangalore, Karnataka, India
- Amarin Investigational Site
Bangalore, Karnataka, India
- Amarin Investigational Site
Bangalore, Karnataka, India
- Amarin Investigational Site
Mysore, Karnataka, India
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2011
- Primary completion
- 31 May 2018
- Completion
- 31 May 2018
- Last update posted
- 14 Apr 2022
- Registered enrollment
- 8,179
- Registry id
- NCT01492361
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.